LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 159

Search options

  1. Article ; Online: Is Aspirin the True Protective Therapy in Coronavirus Disease 2019 Patients?

    Mourad, Jean-Jacques / Suhl, Jaehyo

    Anesthesia and analgesia

    2021  Volume 133, Issue 3, Page(s) e41

    MeSH term(s) Anti-Inflammatory Agents, Non-Steroidal ; Aspirin/adverse effects ; COVID-19 ; Humans ; Platelet Aggregation Inhibitors ; SARS-CoV-2
    Chemical Substances Anti-Inflammatory Agents, Non-Steroidal ; Platelet Aggregation Inhibitors ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2021-08-20
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80032-6
    ISSN 1526-7598 ; 0003-2999
    ISSN (online) 1526-7598
    ISSN 0003-2999
    DOI 10.1213/ANE.0000000000005635
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Tocilizumab for severe COVID-19 pneumonia.

    Mourad, Jean-Jacques / Azria, Philippe

    The Lancet Rheumatology

    2020  Volume 2, Issue 11, Page(s) e659

    Keywords covid19
    Language English
    Publishing date 2020-08-17
    Publishing country England
    Document type Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(20)30282-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The Different Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality.

    Mourad, Jean-Jacques

    Mayo Clinic proceedings

    2016  Volume 91, Issue 7, Page(s) 972

    Language English
    Publishing date 2016-07
    Publishing country England
    Document type Letter
    ZDB-ID 124027-4
    ISSN 1942-5546 ; 0025-6196
    ISSN (online) 1942-5546
    ISSN 0025-6196
    DOI 10.1016/j.mayocp.2016.04.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Interaction between RAAS inhibitors and ACE2 in the context of COVID-19.

    Mourad, Jean-Jacques / Levy, Bernard I

    Nature reviews. Cardiology

    2020  Volume 17, Issue 5, Page(s) 313

    MeSH term(s) Angiotensin-Converting Enzyme 2 ; Betacoronavirus ; COVID-19 ; Cardiovascular System ; Coronavirus Infections ; Humans ; Pandemics ; Peptidyl-Dipeptidase A ; Pneumonia, Viral ; Renin-Angiotensin System/drug effects ; SARS-CoV-2
    Chemical Substances Peptidyl-Dipeptidase A (EC 3.4.15.1) ; ACE2 protein, human (EC 3.4.17.23) ; Angiotensin-Converting Enzyme 2 (EC 3.4.17.23)
    Keywords covid19
    Language English
    Publishing date 2020-03-21
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2490375-9
    ISSN 1759-5010 ; 1759-5002
    ISSN (online) 1759-5010
    ISSN 1759-5002
    DOI 10.1038/s41569-020-0368-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Corrigendum to: Renin Angiotensin Blockers and Cardiac Protection: From Basics to Clinical Trials.

    Lévy, Bernard I / Mourad, Jean Jacques

    American journal of hypertension

    2022  Volume 35, Issue 7, Page(s) 676

    Language English
    Publishing date 2022-04-30
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 639383-4
    ISSN 1941-7225 ; 1879-1905 ; 0895-7061
    ISSN (online) 1941-7225 ; 1879-1905
    ISSN 0895-7061
    DOI 10.1093/ajh/hpac018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?

    le Noble, Ferdinand A C / Mourad, Jean-Jacques / Levy, Bernard I / Struijker-Boudier, Harry A J

    Hypertension (Dallas, Tex. : 1979)

    2023  Volume 80, Issue 5, Page(s) 901–911

    Abstract: Drugs acting by inhibition of the angiogenic action of VEGF (vascular endothelial growth factor) have become major instruments in the treatment of cancer. The downside of their favorable effects in cancer treatment is their frequent cardiovascular side ... ...

    Abstract Drugs acting by inhibition of the angiogenic action of VEGF (vascular endothelial growth factor) have become major instruments in the treatment of cancer. The downside of their favorable effects in cancer treatment is their frequent cardiovascular side effects. The most consistent finding thus far on the cardiovascular side effects of VEGF inhibitors is the high incidence of hypertension. In this short review, we discuss the evidence that hypertension occurring during VEGF inhibitor treatment is caused by microvascular rarefaction. After a review of the role of VEGF in microvascular growth and differentiation, we present evidence from studies in experimental models of hypertension as well as clinical studies on the microvascular network changes during and after VEGF inhibitor treatment.
    MeSH term(s) Humans ; Vascular Endothelial Growth Factor A/metabolism ; Microvascular Rarefaction/chemically induced ; Microvascular Rarefaction/complications ; Microvascular Rarefaction/drug therapy ; Hypertension ; Vascular Endothelial Growth Factors ; Neoplasms/drug therapy ; Angiogenesis Inhibitors/adverse effects
    Chemical Substances Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors ; Angiogenesis Inhibitors
    Language English
    Publishing date 2023-02-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 423736-5
    ISSN 1524-4563 ; 0194-911X ; 0362-4323
    ISSN (online) 1524-4563
    ISSN 0194-911X ; 0362-4323
    DOI 10.1161/HYPERTENSIONAHA.122.19427
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials.

    Chalmers, John / Mourad, Jean-Jacques / Brzozowska-Villatte, Romualda / De Champvallins, Martine / Mancia, Giuseppe

    Journal of hypertension

    2023  Volume 41, Issue 3, Page(s) 508–515

    Abstract: Objective: The aim of this study was to assess the reduction in all-cause death and cardiovascular outcomes associated with the administration of the thiazide-like diuretic indapamide monotherapy or in combination with perindopril as a blood pressure ... ...

    Abstract Objective: The aim of this study was to assess the reduction in all-cause death and cardiovascular outcomes associated with the administration of the thiazide-like diuretic indapamide monotherapy or in combination with perindopril as a blood pressure lowering drug in randomized controlled trials (RCTs).
    Method: Aggregate data from four published RCTs conducted versus matching placebo were pooled: PATS, a 2-year study (indapamide), and PROGRESS, a 4-year study (indapamide and perindopril), both in patients with a history of stroke or transient ischemic attack; ADVANCE, a 4-year study in patients with type 2 diabetes and cardiovascular risk factor (single-pill combination perindopril/indapamide) and HYVET, a 2-year study in very elderly hypertensive individuals (indapamide and an option of perindopril). The pooled effect (fixed and random) estimate (hazard ratio) was reported with corresponding 95% confidence intervals and P values. Treatment discontinuations were also analysed to assess the net benefit of the treatment.
    Results: The population involved 24 194 patients (active: 12 113, placebo: 12 081). The fixed-effects meta-analysis of the three mortality endpoints found low statistical heterogeneity ( I2  = 0). Statistically significant risk reductions in the indapamide with or without perindopril-treated patients as compared to placebo were observed for all-cause death (-15%), cardiovascular death (-21%), fatal stroke (-36%) and all strokes (-27%). Other cardiovascular outcomes were improved (risk reduction, 22 to 36%). As expected, discontinuation rates for safety (two studies) were higher in the active group (6.4 vs. 3.9%), while they were similar when discontinuation for any reason is concerned (18.4 vs. 18.0%).
    Conclusion: Across medium to high cardiovascular risk population, long-term indapamide, mostly combined with perindopril-based treatment, provided evidence of benefit on mortality and morbidity.
    MeSH term(s) Humans ; Aged ; Perindopril/therapeutic use ; Indapamide/therapeutic use ; Antihypertensive Agents ; Hypertension/complications ; Stroke/epidemiology ; Drug Combinations ; Blood Pressure ; Randomized Controlled Trials as Topic
    Chemical Substances Perindopril (Y5GMK36KGY) ; Indapamide (F089I0511L) ; Antihypertensive Agents ; Drug Combinations
    Language English
    Publishing date 2023-01-19
    Publishing country Netherlands
    Document type Meta-Analysis ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 605532-1
    ISSN 1473-5598 ; 0263-6352 ; 0952-1178
    ISSN (online) 1473-5598
    ISSN 0263-6352 ; 0952-1178
    DOI 10.1097/HJH.0000000000003368
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based study.

    Ferrières, Jean / Bruckert, Eric / Farnier, Michel / Krempf, Michel / Mourad, Jean-Jacques / Roux, Baptiste / Schiele, François

    Journal of comparative effectiveness research

    2023  Volume 12, Issue 4, Page(s) e220181

    Abstract: Aim: ...

    Abstract Aim:
    MeSH term(s) Humans ; Hypercholesterolemia/complications ; Hypercholesterolemia/drug therapy ; Cholesterol, LDL ; Cardiologists ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; France ; Anticholesteremic Agents/therapeutic use
    Chemical Substances Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Anticholesteremic Agents
    Language English
    Publishing date 2023-03-08
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2669725-7
    ISSN 2042-6313 ; 2042-6305
    ISSN (online) 2042-6313
    ISSN 2042-6305
    DOI 10.57264/cer-2022-0181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Tocilizumab for severe COVID-19 pneumonia

    Mourad, Jean-Jacques / Azria, Philippe

    The Lancet Rheumatology

    2020  Volume 2, Issue 11, Page(s) e659

    Keywords covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ISSN 2665-9913
    DOI 10.1016/s2665-9913(20)30282-4
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top